PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS
The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of...
Saved in:
Main Authors | , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
12.03.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours.
La presente invencion esta relacionada con una composicion capaz de inhibir el crecimiento de celulas tumorales de diferentes origenes histologicos y de celulas endoteliales activadas; los componentes de dicha composicion son fragmentos polipeptidicos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molecula, los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto anti-tumoral de la composicion; las prodigiosinas en la composicion pueden estar a una concentracion de 0.1 - 100 nM; la accion anti-proliferativa de la composicion esta mediada por mecanismos apoptoticos. Su administracion "in vivo" tiene efecto antitumoral, antiangiogenico y protector contra tumores malignos. |
---|---|
Bibliography: | Application Number: MX20070000339 |